Terms: = Leukemia AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS
494 results:
1. Discovery of Highly Potent and Efficient cbp/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract] [Full Text] [Related]
2. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of CREB Binding and Function with a Dual-Targeting Ligand.
Liu Y; Joy ST; Henley MJ; Croskey A; Yates JA; Merajver SD; Mapp AK
Biochemistry; 2024 Jan; 63(1):1-8. PubMed ID: 38086054
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic targeting of EP300/cbp by bromodomain inhibition in hematologic malignancies.
Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of a potent and selective cbp bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
[TBL] [Abstract] [Full Text] [Related]
6. DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia.
Campolungo D; Salomé M; Biferali B; Tascini AS; Gabellini D
Sci Adv; 2023 Sep; 9(37):eadi3771. PubMed ID: 37713484
[TBL] [Abstract] [Full Text] [Related]
7. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
[TBL] [Abstract] [Full Text] [Related]
8. [A comparative study of the effects of citrate and heparin anticoagulation on coagulation function and efficacy in children with septic shock undergoing continuous blood purification].
Zhong X; Luo S; Ren R; Lai J; Deng G; Zhu H
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):856-859. PubMed ID: 37593866
[TBL] [Abstract] [Full Text] [Related]
9. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.
Salaverria I; Weigert O; Quintanilla-Martinez L
Blood Adv; 2023 Sep; 7(18):5258-5271. PubMed ID: 37561599
[TBL] [Abstract] [Full Text] [Related]
10. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
11. ZNF384-Related Fusion Genes in Acute Lymphoblastic leukemia.
Zhu L; Bai W; Cheng Q; Fang J
Cancer Control; 2023; 30():10732748231182787. PubMed ID: 37306722
[TBL] [Abstract] [Full Text] [Related]
12. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of cbp and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract] [Full Text] [Related]
13. LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation.
Compton SE; Kitchen-Goosen SM; DeCamp LM; Lau KH; Mabvakure B; Vos M; Williams KS; Wong KK; Shi X; Rothbart SB; Krawczyk CM; Jones RG
Mol Cell; 2023 Jun; 83(11):1872-1886.e5. PubMed ID: 37172591
[TBL] [Abstract] [Full Text] [Related]
14. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN
Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414
[TBL] [Abstract] [Full Text] [Related]
15. De novo monocytic-M5b AML with t(8;16) (p11.2; p13.3) KAT6A/crebbp fusion and FLT3-TKD mutation complicated by chemotherapy-induced Takotsubo cardiomyopathy.
Ananthaneni A; Benzar T; Hafiz N; Akabane H
BMJ Case Rep; 2023 Mar; 16(3):. PubMed ID: 36977512
[TBL] [Abstract] [Full Text] [Related]
16. Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia.
Wang L; Gu S; Chen F; Yu Y; Cao J; Li X; Gao C; Chen Y; Yuan S; Liu X; Qin J; Zhao B; Xu P; Liang T; Tong H; Lin X; Feng XH
Signal Transduct Target Ther; 2023 Mar; 8(1):120. PubMed ID: 36959211
[TBL] [Abstract] [Full Text] [Related]
17. HBZ upregulates myoferlin expression to facilitate HTLV-1 infection.
Polakowski N; Sarker MAK; Hoang K; Boateng G; Rushing AW; Kendle W; Pique C; Green PL; Panfil AR; Lemasson I
PLoS Pathog; 2023 Feb; 19(2):e1011202. PubMed ID: 36827461
[TBL] [Abstract] [Full Text] [Related]
18. [Clinical Study on the Relationship between Gene Mutation Profile and Prognosis in Pediatric Acute Lymphocyte leukemia].
Chen Y; Qi SS; Ding LL; DU Y; Song N; Wang Z; Yang L; Sun M; Xiong H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):17-24. PubMed ID: 36765471
[TBL] [Abstract] [Full Text] [Related]
19. Analysis and therapeutic targeting of the EP300 and crebbp acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
[TBL] [Abstract] [Full Text] [Related]
20. Engineered CRISPR prime editors with compact, untethered reverse transcriptases.
Grünewald J; Miller BR; Szalay RN; Cabeceiras PK; Woodilla CJ; Holtz EJB; Petri K; Joung JK
Nat Biotechnol; 2023 Mar; 41(3):337-343. PubMed ID: 36163548
[TBL] [Abstract] [Full Text] [Related]
[Next]
